Harmony Biosciences Files 8-K on Financial Condition

TL;DR

**Harmony Biosciences just dropped an 8-K on its financials, so keep an eye out for details.**

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under the Securities Exchange Act of 1934, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health and operational efficiency, which can influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with current information on Harmony Biosciences' financial health, which is crucial for evaluating the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and does not inherently present new risks, but rather provides information for risk assessment.

Analyst Insight

A smart investor would monitor for the full financial results that this 8-K foreshadows, as the current filing only indicates an update on financial condition without providing specific numbers.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• 001-39450 (dollar_amount) — Commission File Number
• HRMY (company) — trading symbol for Harmony Biosciences
• The Nasdaq Global Market (company) — exchange where Harmony Biosciences' stock is registered

Forward-Looking Statements

• Harmony Biosciences will release more detailed financial results soon. (Harmony Biosciences Holdings, Inc.) — high confidence, target: Q1 2024

FAQ

From the Filing

0001558370-24-000128.txt : 20240108 0001558370-24-000128.hdr.sgml : 20240108 20240108083012 ACCESSION NUMBER: 0001558370-24-000128 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24518485 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240108x8k.htm 8-K 0001802665 false 0001802665 2024-01-08 2024-01-08 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): January 8, 2024 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 2.02.     Results of Operations and Financial Condition. On January 8, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2023. In addition, the Company provided guidance related to 2024 net product revenue and disclosed the number of shares repurchased during the fourth quarter and year ended December 31, 2023. A copy of this press release is attached as